Main info

Identifier:

HOVON 59 AML SAKK OSHO

Sponsor:

HOVON

Included patients:

22

Active sites:

5

(of 5)

Title:

Anti-CD33 antibody (Gemtuzumab Ozogamicin) prior to allografting with reduced intensity conditioning in patients with acute myelocytic leukemia (AML) or myelodysplasia: a phase II feasibility study.

Timeline

Details

Phase:

Prospective Phase II study

Monitoring Type:

Objectives:

Eligibility

Inclusion Criteria:

• HLA identical sibling donor, or molecularly matched (9/10 or 10/10) unrelated donor
• Donor must consent to hematopoietic stem cell harvest from peripheral blood (preferably) or from bone marrow
• Donor meets the institutional guidelines for stem cell harvest
• Age = 16 years or = 75 years

Exclusion Criteria:

• Pregnancy
• HIV positivity
• Current serious systemic illness

Participating Sites

= Active hospitals

= Inactive hospitals